Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.59 |
| ▸ | NPC1 | O15118 | 6/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.59 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | EGFR | P00533 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4503675 | 1.00 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL4897631 | 0.87 | RAB9A (0.49) | RAB9ANPC1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL4512772 | 0.87 | ALDH1A1 (0.53) | RAB9ANPC1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL4502890 | 0.87 | RAB9A (0.49) | RAB9ANPC1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL4900705 | 0.87 | ALDH1A1 (0.53) | RAB9ANPC1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL4900690 | 0.87 | LMNA (0.60) | RAB9ANPC1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL4513276 | 0.87 | LMNA (0.60) | RAB9ANPC1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL4894625 | 0.86 | SMN1; SMN2 (0.50) | RAB9ANPC1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL4493586 | 0.86 | SMN1; SMN2 (0.50) | RAB9ANPC1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL4513294 | 0.85 | MTNR1B (0.57) | RAB9ANPC1SMN1; SMN2LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7494989-B2 | Pyridine compounds useful as N-type calcium channel antagonists | AJINOMOTO CO., INC. (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20080070903-A1 | NEW PYRIMIDINE DERIVATIVES AND NEW PYRIDINE DERIVATIVES | AJINOMOTO CO., INC (JP) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070903-A1 | NEW PYRIMIDINE DERIVATIVES AND NEW PYRIDINE DERIVATIVES | P2RY10, CACNA1B, CACNA1E | RAB9A 1373/4885NPC1 1982/4885SMN1; SMN2 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.